Clinical trial
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)
ClinicalTrials.gov ID: NCT05026866
Sponsor: Eli Lilly and Company
Information provided by: Eli Lilly and Company (Responsible Party)
Last Update Posted: 2023-10-17
Brief Summary:
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).
Official Title:
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Intervention / Treatment:
- Drug: Donanemab
- Drug: Placebo
| Category | Value |
|---|---|
| Study Start (Actual) | 2021-08-27 |
| Primary Completion (Estimated) | 2027-10-25 |
| Study Completion (Estimated) | 2027-11-08 |
| Enrollment (Estimated) | 2600 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers |
18284
I5T-MC-AACM (Other Identifier) (OTHER: Eli Lilly and Company) |